GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.
CytoMed Therapeutics Capex-to-Revenue Historical Data
The historical data trend for CytoMed Therapeutics's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of CytoMed Therapeutics's Capex-to-Revenue
For the Biotechnology subindustry, CytoMed Therapeutics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytoMed Therapeutics's Capex-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where CytoMed Therapeutics's Capex-to-Revenue falls into.
CytoMed Therapeutics Capex-to-Revenue Calculation
CytoMed Therapeutics's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
CytoMed Therapeutics Capex-to-Revenue Related Terms
Thank you for viewing the detailed overview of CytoMed Therapeutics's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
CytoMed Therapeutics (CytoMed Therapeutics) Business Description
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is majority revenue generator.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GDTC has been successfully added to your